Patents by Inventor Zuhui Zhang

Zuhui Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITION OF RAS
    Publication number: 20250084079
    Abstract: Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12D or G12V mutation or wild-type KRAS) and treating diseases or disorders such as cancers in subjects in need thereof.
    Type: Application
    Filed: January 5, 2023
    Publication date: March 13, 2025
    Inventors: Bin Wang, Rui Xu, Eli Wallace, Zuhui Zhang, Felice Lightstone, Yue Yang, David Michael Turner, Anna Elzbieta Maciag, Dhirendra Kumar Simanshu, Albert Hay Wah Chan
  • COMPOSITIONS AND METHODS FOR INHIBITION OF RAS
    Publication number: 20240300964
    Abstract: Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12C mutation) and treating diseases or disorders such as cancers in subjects in need thereof.
    Type: Application
    Filed: July 22, 2022
    Publication date: September 12, 2024
    Inventors: Bin Wang, Rui Xu, Eli Wallace, Zuhui Zhang, David Michael Turner, Anna Elzbieta Maciag, Dhirendra Kumar Simanshu, Albert Hay Wah Chan, Tao Liao, Christopher John Brassard, Yue Yang, Paola Bisignano, Felice Lightstone
  • COMPOSITIONS AND METHODS FOR INHIBITING KRAS
    Publication number: 20240246954
    Abstract: Provided herein are compounds of formula (I) and (II), or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12D mutation) and treating diseases or disorders such as cancers in subjects in need thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: July 25, 2024
    Inventors: Bin Wang, Rui Xu, Eli Wallace, Felice Lightstone, Yue Yang, Paola Bisignano, Anna Elzbieta Maciag, David Michael Turner, Dhirendra Kumar Simanshu, Albert Hay Wah Chan, Zuhui Zhang, Christopher John Brassard, Tao Liao
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION
    Publication number: 20240002344
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
    Type: Application
    Filed: August 27, 2021
    Publication date: January 4, 2024
    Inventors: Zuhui ZHANG, Xiaoti Zhou, Michael P. Arend, Christian Hauge Kjaergaard
  • TDO2 Inhibitors
    Publication number: 20220306635
    Abstract: Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Application
    Filed: October 12, 2020
    Publication date: September 29, 2022
    Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
  • TDO2 Inhibitors
    Patent number: 10800780
    Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 13, 2020
    Assignees: Genentech, Inc., NewLink Genetics Corporation
    Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
  • TDO2 Inhibitors
    Publication number: 20190016726
    Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 17, 2019
    Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu